Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz) in patients with previously resected colon polyps and first-degree female relatives of breast cancer patients

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3870-3877

  Benson, Al B ^a   Olopade, Olufunmilayo I ^b   Ratain, Mark J ^b   Rademaker, Alfred ^a   Mobarhan, Sohrab ^c,d   Stucky Marshall, Lisa ^a   French, Suzanne ^a   Dolan, M Eileen ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Ingalls Cancer Research Center   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; GLUTATHIONE TRANSFERASE; OLTIPRAZ;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLON POLYP; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RECTUM BIOPSY; RELATIVE;

ANTICARCINOGENIC AGENTS; BIOPSY; BREAST NEOPLASMS; COLONIC POLYPS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEAT; HUMANS; LYMPHOCYTES; MALE; PYRAZINES; RECTUM; TIME FACTORS;

EID: 0033765152     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review
2. 1 in the rat
3. Mechanisms of protection against aflatoxin tumorigenicity of rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones
4. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiolethione
5. 1 metabolism
6. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3- thione (oltipraz) on carcinogenesis induced by benzo(a)pyrene, dimethylnitrosamine, and uracil mustard
7. Oltipraz: Clinical opportunities for cancer chemoprevention
8. Chemoprevention effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats
9. Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by ethoxymethane in male F344 rats
10. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species
11. 14C-oltipraz in animals
12. Oltipraz: A laboratory and clinical review
13. Increased green and yellow vegetable intake and lower cancer deaths in an elderly population
14. Diet in the epidemiology of cancer of the colon and rectum
15. A case-control study of large bowel cancer in Japan
16. Case-control study of dietary etiological factors: The Melbourne colorectal cancer study
17. Epidemiologic studies on Brassica vegetables and cancer risk
18. 1 in rats fed cauliflower
19. Contributions of aflatoxin-induced serum α fetoprotein in rats fed cauliflower
20. 1-induced rat plasma α-fetoprotein elevation, hepatic tumorigenesis and mutagenicity of urine
21. Chemoprevention of cancer
22. Isolierung und identifizierung organischer polysulfide aus krolut and ihre beziehung zum brassica faktor
23. Uber das vorkommen von trithionen in brassica pflanzen
24. Biochemical effects of dithiolethiones
25. Y-S induction of NAD(P)H:Quinone reductase in human blood peripheral lymphocytes
26. 1,2-Dithiole-3-thione analogs: Effects of NAD(P)H:Quinone reductase and glutathione levels in murine hepatoma cells
27. Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases
28. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent
29. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz
30. Oltipraz antischistosomal efficacy in Sudanese infected with Schistosoma mansoni
31. Dose-finding trial using oltipraz to treat school children infected with Schistosoma mansoni in Gezira
32. Assessment of 35972 RP (oltipraz) a new antischistosomal drag against Schistosoma haematobium, Schistosoma mansoni, and Schistosoma intercalatum
33. Dose-ranging clinical trial with oltipraz in Schistosomiasis mansoni
34. Diet-controlled blood levels of oltipraz in healthy male subjects
35. Clinical pharmacology studies of oltipraz - A potential chemopreventive agent
36. Oltipraz in individuals at high risk for colorectal cancer
37. 1 by glutathione and glutathione-one transferases in vitro
38. Phase I study of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione [oltipraz: RP 35972] in male patients with previously resected colon polyps and first degree relatives of breast cancer patients
39. Comparison of the metabolism of oltipraz is the mouse, rat and monkey and in man. Distribution of the metabolites in each species
40. 14C-oltipraz in animals
41. Oltipraz: A laboratory and clinical review
42. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz
43. Effect of cysteine on oltipraz blood levels of in green monkeys (Cercopithecus aethiops)
44. High performance liquid chromatography method for the analysis of oltipraz in human serum and urine
45. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1g
46. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues
47. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine
48. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
49. Glutathione S-transferase, the first enzymatic step in mercapturic acid formation
50. Oltipraz chemoprevention trial in Qidong, People's Republic of China: Study design and clinical outcomes